title: Concomitant triptan and SSRI or SNRI use: a risk for serotonin syndrome.
abstract: OBJECTIVE
  To discern the prevalence of concomitant use of a triptan and a selective serotonin reuptake inhibitor (SSRI) or a selective serotonin/norepinephrine reuptake inhibitor (SNRI) in the USA.
  
  
  BACKGROUND
  In July, 2006, the US Food and Drug Administration warned patients and health-care professionals to be aware that use of a triptan in combination with an SSRI or an SNRI may result in a potentially life-threatening problem known as serotonin syndrome.
  
  
  METHODS
  We used weighted data from the US National Ambulatory Medical Care Survey for years 2003 and 2004 to derive national estimates of the number of office-based visits documenting concomitant use of a triptan and an SSRI or an SNRI.
  
  
  RESULTS
  During the time frame 2003-04, an annualized mean of 3,874,367 patients were prescribed a triptan, and 50,402,149 patients were prescribed an SSRI or an SNRI. An annualized mean of 694,276 patients were simultaneously prescribed or continued use of a triptan along with an SSRI or SNRI.
  
  
  CONCLUSIONS
  Our study documents that 1.3% of patients prescribed a triptan or an SSRI or an SNRI were prescribed the potentially fatal combination. While this is a small fraction overall, the actual number of patients on a nationwide basis is significant (n=694,276).
authors.affiliation: Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Pullman, WA 99164-6510, USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Sclar
authors.forename: Linda M
authors.initials: LM
authors.lastname: Robison
authors.forename: Tracy L
authors.initials: TL
authors.lastname: Skaer
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D005260:Female; D019538:Health Care Surveys; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012306:Risk; D020230:Serotonin Syndrome / Q000139:chemically induced* / Q000453:epidemiology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D014363:Tryptamines / Q000009:adverse effects*
chemical_list: D018759:Adrenergic Uptake Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors; D014363:Tryptamines